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We examined cell isolation, viability, and growth in adipose-derived stem cells harvested from whole adipose tissue subject to
different cryopreservation lengths (2–1159 days) from patients of varying ages (26–62 years). Subcutaneous abdominal adipose
tissue was excised during abdominoplasties and was cryopreserved. The viability and number of adipose-derived stem cells isolated
were measured after initial isolation and after 9, 18, and 28 days of growth. Data were analyzed with respect to cryopreservation
duration and patient age. Significantly more viable cells were initially isolated from tissue cryopreserved <1 year than from tissue
cryopreserved >2 years, irrespective of patient age. However, this difference did not persist with continued growth and there were
no significant differences in cell viability or growth at subsequent time points with respect to cryopreservation duration or patient
age. Mesenchymal stem cell markers were maintained in all cohorts tested throughout the duration of the study. Consequently,
longer cryopreservation negatively impacts initial live adipose-derived stem cell isolation; however, this effect is neutralized with
continued cell growth. Patient age does not significantly impact stem cell isolation, viability, or growth. Cryopreservation of adipose
tissue is an effective long-term banking method for isolation of adipose-derived stem cells in patients of varying ages.

1. Introduction
Adipose-derived stem cells (ASCs) are adult mesenchymal
stem cells that have garnered significant attention since their
description in humans in 2001 by Zuk et al. subsequent to
their initial identification in animal models [1, 2]. This is in
part because the use of embryonic stem cells has been limited
by multiple ethical, functional, and therapeutic dilemmas
[3] and because the isolation of other adult multipotent
stem cells, such as bone marrow derived stem cells, often
requires complex and painful harvesting procedures resulting
in low cellular yields [2]. In contrast, ASCs possess multiple

characteristics that make them ideal for use in regenerative
medicine applications. ASCs are multipotent, are abundant
in human subcutaneous adipose tissue [4, 5], and can be
harvested using minimally invasive procedures [4, 6, 7].
Significantly, the therapeutic effects of ASCs can also be garnered by the use of ASC-enriched stromal vascular fractions
(SVF) without additional enzymatic isolation, a preparation
consistent with good manufacturing practice (GMP), as
defined by both the European Medicines Agency and the
Food and Drug Administration [8].
Because ASCs can differentiate into any cell type of mesenchymal origin, including muscle, fat, bone, and cartilage,
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they have been hypothesized to have broad clinical applications in regenerative medicine including cellular repair
after myocardial infarction, breast reconstruction, bone and
cartilage regeneration after trauma, cancer, and autoimmune
disorders [9]. Recent data suggest that ASCs are further
able to differentiate into hepatocytes [10] and neural cells
[11], extending their utility to the treatment of liver failure
and brain injury, among others. In addition to their ability
to differentiate and directly renew cellular populations, the
benefits of ASCs further extend to their strong paracrine
signaling mechanisms that confer protective effects in multiple pathological pathways, including inflammation, wound
healing, neurodegeneration, and cancer [12, 13]. As the potential therapeutic applications of ASCs continue to expand,
questions regarding the optimal technical management of
ASCs become increasingly important to answer. Although we
have increasing supplies of ASCs from the growing number
of abdominoplasties and liposuction procedures performed
each year [4], most current ASC investigations are performed
on freshly isolated cells. These ASCs may not accurately
reflect the clinical response when ASCs are isolated from
cryopreserved specimens, as would be expected in future
clinical scenarios with the rapid development of biobanking.
Consequently, further research is required to examine the
effects of tissue cryopreservation and ASC biobanking to
safely and effectively optimize the therapeutic benefits of
ASCs.
Several animal models have previously examined the
effect of cryopreservation on ASCs. It has been shown that
human lipoaspirate frozen for seven days and injected into
mice displayed similar fat graft growth and resorption rates
compared to freshly injected lipoaspirate [14]. Likewise, fat
isolated from the inguinal region of mice that was frozen
for six months demonstrated similar viability as freshly
isolated tissue injected into mice [15]. A porcine model
further demonstrated that isolated ASCs may be frozen for
three to twelve months without inducing changes in surface
markers, doubling time, and senescence markers or causing
chromosomal abnormalities [16].
A limited number of studies in humans have examined
the effects of cryopreservation on lipoaspirate and isolated
ASCs. Lipoaspirate frozen for less than a month demonstrated no change in phenotypic markers, proliferative capacity, or differentiation potential [17]. Furthermore, cryopreserved ASCs have been shown to retain their differentiation
potential and capacity when frozen for up to six months
[18]. A study of almost 2500 lipoaspirates frozen for 3–
6 months and subsequently used for facial rejuvenation
revealed similar results in surgeon and patient satisfaction
when compared to freshly injected lipoaspirate [19], though
this study was not quantitative. Despite these pieces of data,
there remains a paucity of studies examining the effects
of long-term cryopreservation on primary human adipose
tissue as a natural biobanking reservoir of ASCs. To our
knowledge, the only other investigation that examined the
effects of long-term (≤4 years) cryopreservation on human
ASCs focused on marker profile and differentiation capabilities but not ASC proliferative ability [20]. Several studies have
suggested that suboptimal cryopreservation may negatively
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impact ASC membrane integrity and function [21–23]. In
addition, advancing patient age is believed to correlate with
impaired ASC differentiation and growth profiles [24, 25]. To
address these observations, we examine here whether there is
a negative correlation between ASC isolation, viability, and
growth in relation to increased duration of adipose tissue
cryopreservation and advancing patient age.

2. Materials and Methods
2.1. Adipose Tissue Harvest. Subcutaneous abdominal fat was
excised during abdominoplasties between November 2010
and January 2015 from patients of different ages. Tissue was
obtained from 32 (1 male and 31 female) patients, chosen
at random. All procedures were conducted using informed
consent under the University of Pennsylvania IRB approval
(Protocol number 812150). On the day of the procedure,
tissue was excised, maintained on ice, transported to the lab,
aliquoted into 50 mL conical tubes, and stored at −70∘ C. No
cryopreservation or other agents were used in the freezing of
the whole adipose tissue specimens. Tissue from 32 patients
with an age range of 26–62 years (average 43.2 ± 9.7 years)
and cryopreservation time (−70∘ C) of 2–1159 days (average
596.4 ± 369.9 days) was analyzed. Average patient BMI was
28 ± 5 kg/m2 and did not differ significantly between the
young (27±3 kg/m2 ) and advanced age groups (29±6 kg/m2 ).
The majority of patients were of Caucasian descent (87%),
while the remaining patients were of African American
descent (13%), without significant differences between the
young and advanced age groups. No patients had been diagnosed as prediabetic or diabetic prior to adipose isolation.
2.2. Isolation of Adipose-Derived Stem Cells (ASC). Standard
methods for isolating and purifying ASCs, separating them
from the stromal vascular fraction containing fibroblasts,
pericytes, preadipocytes, monocytes, and macrophages, as
well as smooth muscle, endothelial progenitor, and red
blood cells of the SVF, have been well established and were
employed here [2, 26, 27]. At defined dates, whole adipose
tissue was thawed in the original 50 mL conical tubes at
room temperature and stem cells were isolated from 10 g
of tissue using a standard collagenase protocol [28]. Briefly,
tissue was quickly washed (1xPBS/penicillin/streptomycin),
minced, and digested in 15 mL 37∘ C warmed Digestion
Media (1x Dulbecco’s Modified Eagle Medium (DMEM,
Gibco of Life Technologies Co., Norwalk, CT) with 0.1%
collagenase (Worthington Biomedical Co, Lakewood, NJ),
1% Penicillin/Streptomycin (Corning, Christiansburg, VA),
0.008% Biotin (Sigma, Bloomington, MN), and 0.004%
Pantothenate (Sigma, Bloomington, MN)) while shaking at
37∘ C and 180 rpm for one hour (vortexing each sample
every 10 minutes). Samples were removed and 20 mL DMEM
was added to each tube. Samples were then filtered using
sterile funnels and gauze and spun at 800 g for ten minutes
to allow for complete cell/layer-separation. The lipid layer,
adipocyte layer, and media were removed carefully, leaving
the Stromal Vascular Fraction pellet. Red blood cell lysis
buffer (ZenBio, Durham, NC) was added to each tube and
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the pellet was allowed to lyse in buffer for 10 minutes at room
temperature. 15 mL of DMEM was added and the tubes were
spun at 800 g for 10 minutes. The supernatant was removed
and 1 mL of Stem Cell Media (1xDulbecco’s Modified Eagle
Medium/F12 (DMEM/F12, Gibco of Life Technologies Co.,
Norwalk, CT) supplemented with 1% Penicillin/Streptomycin
(Gibco of Life Technologies Co., Norwalk, CT) and 10% FBS
(Serum Source International, Charlotte, NC)). The dissolved
SVF pellet containing ASCs was transferred to a 6-well plate,
after filtration through a 70 𝜇m cell strainer (FisherBrand,
Pittsburgh, PA). An additional 2 mL of Stem Cell Media was
rinsed through the strainer to obtain any residual cells from
the filter. The plate was incubated at 37∘ C in 5% CO2 and
the Stem Cell Media was changed 48 hours after plating to
remove debris and nonadherent cells.
2.3. ASC Analysis. Cells from the SVF pellet were grown in
Stem Cell Media (as described above), that was changed twice
weekly. In accordance with accepted ASC isolation protocols,
48 hours after SVF pellet plating, viable and adherent cells
were considered to represent adipose-derived stem cells [8,
17, 26]. 17 days after SVF pellet plating (initial ASC analysis),
the number of live cells and cell viability were measured using
the Countess Automated Cell Counter (Invitrogen, Carlsbad,
CA) to quantify cell number and cell viability was determined
by the exclusion of Trypan blue stain (Life Technologies,
Norwalk, CT). At this time, representative ASC lines (𝑛 =
28, p0-1) were replated to a density of 1 × 105 cells/well
on a 12-well plate. Cells were subsequently measured again
at 9, 18, and 28 days after the initial analysis. Data were
analyzed with respect to the following independent variables:
cryopreservation time: <1 year (𝑁 = 10), 1-2 years (𝑁 = 5),
and >2 years (𝑁 = 17), and patient age: <40 years (𝑁 = 12)
versus ≥40 years (𝑁 = 20) and <50 years (𝑁 = 23) versus
≥50 years (𝑁 = 9).
2.4. FACS Analysis. ASCs were grown until confluent, trypsinized, and pelleted by centrifugation at 500 g for five
minutes. For fluorescence-activated cell sorting (FACS) analysis, approximately 2.5 × 105 cells were resuspended in
100 𝜇L FACS buffer containing 0.1% BSA (Fisher Scientific,
Philadelphia, PA) in PBS. For FACS analysis of surface
markers, each sample was incubated with 5 𝜇L of anti-human
PE-conjugated, PE-Cy7-conjugated, or APC-conjugated antibodies: CD34 (BD Biosciences, San Jose, CA), CD45, and
CD105 (eBioscience, San Diego, CA), and then diluted in
FACS buffer for 30 minutes at 4∘ C. Unstained cells and singlecolor-stained cell controls were prepared for compensation.
After incubation, the excess and nonspecifically bound antibodies were removed by multiple washes in FACS buffer.
Cells were pelleted and resuspended in 500 𝜇L of FACS
buffer and transferred to polypropylene tubes. Propidium
Iodide (Sigma, Bloomington, MN) staining was used to
determine cell viability. The surface expression of live cells
(approximately 104 cells per patient) was characterized by
FACS (Wistar Institute, Philadelphia PA) using the BD
FACSCalibur flow cytometer (BD Biosciences, San Jose, CA,
USA). Results were analyzed using FlowJo software version
10.0.6 (Three Star Data Analysis Software, Ashland, OR).
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2.5. Adipogenesis Assay. ASCs were seeded in a 24-well plate
at a density of 5 × 103 cells/well and grown in adipogenic
media comprised of DMEM/F12 Medium supplemented with
10% FBS, 1 𝜇mol/L dexamethasone, 10 𝜇g/mL insulin, and
0.5 mmol/L isobutylmethylxanthine (Sigma, Bloomington,
MN). ASCs were grown for 14 days, with media changes every
3 days, after which ASCs were stained with Oil Red O (Sigma,
Cloomington, MN) as per manufacturer’s protocol.
2.6. Osteogenesis Assay. ASCs were seeded in a 24-well plate
at a density of 5 × 103 cells/well and grown in osteogenic
media comprised of DMEM/F12 Medium supplemented with
10% FBS, 0.1 𝜇mol/L dexamethasone, 10 mmol/L 𝛽-glycerol
phosphate, and 50 𝜇mol/L ascorbate. Cells were grown for 21
days, with media changes every 3-4 days, after which ASCs
were stained with alkaline phosphatase (Amresco, Solon,
OH) as per manufacturer’s protocol.
2.7. qRT-PCR Analysis. Total mRNA was extracted from
individual ASC lines (𝑛 = 11) and the human lung fibroblast
IMR90 cell line (𝑛 = 3) using standard TRIzol-chloroform
extraction (Invitrogen, Carlsbad, CA) and the RNeasy Mini
Kit (Qiagen, Valencia, CA). cDNA was produced using a
High Capacity RNA-to-cDNA Kit (Applied Biosystems of
Life Technologies Co., Norwalk, CT) as per manufacturer
instructions. Forward and reverse primers were designed for
GAPDH (F: CGCTCTCTGCTCCTCCTGTT, R: GCGACGCAAAAGAAGATG), Nanog (F: CTGTGATTTGTGGGCCTGAA, R: CAGAAGACATTTGCAAGGATGG), Oct4 (F:
GCCCGAAAGAGAAAGCGAAC, R: CAGGTTGCCTCTCACTCGGT), and Sox2 (F: GCAAGATGGCCCAGGAGAA, R: GCTTGCTGATCTCCGAGTTGT). qPCR was prepared as a 10 𝜇L reaction using a SYBR Green PCR Master
Mix Kit (Applied Biosystems of Life Technologies Co., Norwalk, CT), run on a 7900HT Fast Real-Time PCR machine
(Applied Biosystems of Life Technologies Co., Norwalk, CT),
and analyzed using SDS 2.4 software. Transcript levels were
normalized against expression levels of the housekeeper
GAPDH using the 2−ΔΔCT method. Three technical replicates
were performed for each assay and the results were averaged.
2.8. Statistical Analysis. Student 𝑇-test and multivariate regression analysis were performed using Microsoft Excel
software (Microsoft, Redmond, WA). Unpaired, two-tailed 𝑇tests were utilized to generate 𝑃 values comparing all involved
cohorts.

3. Results
3.1. ASC Isolation and Growth Relative to Cryopreservation
Duration. Live ASCs isolated ranged from 0 to 5.9 × 104
cells/g adipose tissue harvested, averaging 2.95×104 ±2.5×104
cells/g tissue. ASC isolation from frozen tissue of cohorts <1
year, 1-2 years, and >2 years had average live cell count values
of 4.06 × 104 ± 1.36 × 104 cells/g tissue, 2.29 × 104 ± 2.24 × 104
cells/g tissue, and 1.87 × 104 ± 1.12 × 104 cells/g tissue,
respectively. We observed an inverse relationship between the
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Figure 1: Live ASC isolation relative to duration of cryopreservation. (a) ASCs were isolated from 32 patients whose adipose tissue was
cryopreserved for varying amounts of time (range 2–1159 days, average 596.4 × 104 ± 369.9 × 104 cells/g tissue). Live ASCs isolated ranged
from 0 to 95.5 × 104 cells/g adipose, average 63.8 × 104 ± 30.6 × 104 cells/g tissue, showing a trend toward decreased live ASC isolation with
increasing ASC cryopreservation duration. (b) Live cell count was compared relative to cryopreservation duration in 3 cohort groups: <1 year
(𝑁 = 10), 1-2 years (𝑁 = 5), and >2 years (𝑁 = 17). A significant decrease in live ASC isolation was observed between the >2 years and
<1 year cryopreservation duration cohorts; 𝑃 = 0.0003. (c) Patient age was compared for each of the cryopreservation cohort groups and no
significant differences were found between any group; 𝑃 > 0.05.

number of live ASCs isolated in relation to the number of
days the tissue was frozen (𝑅2 = 0.1093, Figure 1(a)). There
was a significantly greater number of live ASCs isolated from
samples frozen <1 year compared to those frozen >2 years
(𝑃 = 0.0003). No significant differences were found between
other groups (Figure 1(b)). Multivariate regression analysis
demonstrated no significant difference in the number of
cells isolated relative to patient age or other demographic
variables (𝑃 > 0.05). In contrast, cryopreservation length was
independently associated with initial number of cells isolated
irrespective of patient age (𝑃 < 0.001, Figure 1(c)).
Tissue cohorts of cryopreservation duration of <1 year, 1-2
years, and >2 years demonstrated average viability of 76.05 ±
18.36%, 59.83 ± 39.68%, and 56.54 ± 32.99%, respectively
(Figure 2). No significant differences were observed between
the three groups, although a negative trend between the <1
year and >2 years cohorts was observed (𝑃 = 0.055, Figure 2).
ASCs from each patient were plated to a density of 1 × 105
cells/well after initial analysis and subsequently counted 9, 18,
and 28 days later to examine delayed effects on cell growth

secondary to cryopreservation. We observed no significant
differences in ASC growth when comparing duration of
cryopreservation for the <1 year, 1-2 years, and >2 years
cohorts when cell number was analyzed after 9 days (2.31 ×
105 ± 0.86 × 105 cells, 1.56 × 105 ± 0.49 × 105 cells, and
1.61×105 ±0.75×105 cells, resp.), 18 days (4.88×105 ±2.47×105
cells, 4.42 × 105 ± 2.66 × 105 cells, and 3.61 × 105 ± 2.44 × 105
cells, resp.), or 28 days in culture (10.12×105 ±4.27×105 cells,
8.21 × 105 ± 2.8 × 105 cells, and 8.33 × 105 ± 5.48 × 105 cells,
resp.; Figures 3(a)–3(c)).
3.2. ASC Isolation and Growth Relative to Patient Age. Live
ASCs isolated ranged from 0 to 5.9 × 104 cells/g tissue,
averaging 2.95 × 104 ± 2.5 × 104 cells/g tissue with no clear
correlation between ASC isolation and patient age (Figure 4).
The initial live cells were counted for each frozen tissue
sample and compared between the following age cohort pairs:
<40 years versus ≥40 years (2.65× 104 ± 1.8 × 104 cells/g tissue
and 2.6 × 104 ± 1.65 × 104 cells/g tissue, resp.), <50 years
versus ≥50 years (2.44 × 104 ± 1.48 × 104 cell/g tissue and

Cell viability
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Figure 2: Initial ASC viability relative to cryopreservation duration. (a) A trend toward decreasing ASC viability with increasing ASC
cryopreservation duration was observed. (b) ASC viability was compared relative to cryopreservation duration in 3 cohort groups: <1 year
(𝑁 = 10), 1-2 years (𝑁 = 5), and >2 years (𝑁 = 17). No significant differences were observed between the three groups.

3.07 × 104 ± 2.14 × 104 cells/g tissue, resp.), and <40 years
versus ≥50 years (2.65 × 104 ± 1.8 × 104 cells/g tissue and
3.07 × 104 ± 2.14 × 104 cells/g tissue, resp.). No significant
differences in live ASC isolation were observed between any
of the age cohorts, 𝑃 > 0.05 (Figure 4).
Similarly, no significant differences in initial ASC viability relative to patient age were observed between groups,
although a modest increase with advancing patient age was
noted (Figure 5). ASC viability was compared between the
following age cohorts: <40 years versus ≥40 years (54.13 ±
35.61% and 68.73 ± 27.29%, resp.), <50 years versus ≥50 years
(61.8 ± 31.85% and 66.94 ± 30.03%, resp.), and <40 years
versus ≥50 years (54.13 ± 35.61% and 66.94 ± 30.03%, resp.).
No significant differences in ASC viability were observed
between any of these age cohorts, 𝑃 > 0.05 (Figure 5).
ASCs from each patient were plated to a density of 1 × 105
cells/well and counted 9, 18, and 28 days later to examine
and to characterize the effect of patient age on continued
ASC growth. We observed no significant differences in ASC
growth relative to patient age when the average cell number
was compared for the following age groups: (1) <40 years
versus ≥40 year cohorts after 9 days of growth (1.73 × 105 ±
0.7×105 cells and 2.14×105 ±0.88×105 cells, resp.), 18 days of
growth (3.85 × 105 ± 2.13 × 105 cells and 4.85 × 105 ± 2.59 × 105
cells, resp.), or 28 days of growth (9.09 × 105 ± 3.22 × 105
cells and 9.49 × 105 ± 5.2 × 105 cells, resp.) in culture; (2)
<50 years versus ≥50 year cohorts after 9 days of growth
(1.9 × 105 ± 0.75 × 105 cells and 2.29 × 105 ± 1.04 × 105
cells, resp.), 18 days of growth (4.44 × 105 ± 2.44 × 105 cells
and 4.78 × 105 ± 2.63 × 105 cells, resp.), or 28 days of growth
(9.92 × 105 ± 4.49 × 105 cells and 6.41 × 105 ± 2.05 × 105 cells,
resp.) in culture; (3) <40 years versus ≥50 cohorts after 9 days
of growth (1.73×105 ±0.7×105 cells and 2.29×105 ±1.04×105
cells, resp.), 18 days of growth (3.85 × 105 ± 2.13 × 105 cells
and 4.78 × 105 ± 2.63 × 105 cells, resp.), or 28 days of growth
(9.09 × 105 ± 3.22 × 105 cells and 6.41 × 105 ± 2.05 × 105 cells,
resp.; Figures 6(a)–6(c)).

3.3. ASC Phenotype Confirmation. To confirm the stem cell
phenotype of ASCs isolated from cryopreserved adipose, cells
from representative samples were analyzed via FACS analysis
for the following markers: CD105, CD34, and CD45. CD105
served as a positive marker of human mesenchymal stem
cells, CD45 as a negative marker for mesenchymal stem cells,
and CD34 as a variable mesenchymal stem cell marker that
is frequently lost upon extended growth in culture. As predicted, the great majority of ASCs were CD105+ and CD45−
(Figure 7(a)), while the CD34 mark was variable, consistent
with prior studies (data not shown). In addition, we observed
ASCs isolated from all subgroups to be capable of undergoing
both osteogenic and adipogenic differentiation, as demonstrated by positive staining with alkaline phosphatase and Oil
Red O, respectively (Figure 7(b)). Finally, we observed the
expected increased expression of pluripotency genes Nanog,
Sox2, and Oct4 via qRT-PCR within representative ASC cell
lines (𝑛 = 11) comprising a range of patient ages (26–62
years) and cryopreservation times (2–1159 days) as compared
to IMR90 (𝑛 = 3) controls (Figure 7(c)).

4. Discussion
Because they are easily harvested, abundant, and able to
differentiate into a wide variety of cell types, ASCs have the
potential to become a powerful tool in regenerative medicine
[4–7]. The use of fresh adipose tissue for ASC isolation
is not feasible in many clinical or research scenarios, as
therapeutic interventions and research investigations may
be required months or years after tissue harvest. Unfortunately, our current understanding of available long-term
biobanking/preservation methods for ASC isolation remains
inadequate for conducting safe and effective ASC-based
interventions. While several recent studies evaluated the
efficacy of adipose tissue cryopreservation on ASCs, to date
most research has examined animal models [14–17], used
a short interval of cryopreservation [18, 19, 29, 30], or has
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Figure 3: Live ASCs during extended cell growth relative to cryopreservation duration. ASCs from each patient were plated to a density of
1 × 105 cells/well and counted after (a) 9, (b) 18, and (c) 28 days to characterize the effect of cryopreservation duration on continued ASC
growth. We observed sustained ASC growth irrespective of cryopreservation duration. Cell counts were compared relative to cryopreservation
duration in 3 cohort groups: <1 year (𝑁 = 10), 1-2 years (𝑁 = 5), and >2 years (𝑁 = 17), and were not found to be significantly different.

been limited to ASC differentiation and marker expression
analyses [20]. To address these limitations, we investigated
the effects of long-term adipose tissue cryopreservation and
patient age on human ASC isolation, viability, and growth.
Our findings suggest that long-term cryostorage (>2
years) significantly reduces the number of live ASCs isolated relative to short-term cryostorage (<1 year, Figure 1).
Furthermore, ASCs isolated from longer preserved adipose
tissue demonstrate a trend toward reduced viability (<1
year versus >2 years, 𝑃 = 0.055, Figure 2). These findings
are consistent with recent data demonstrating that stem
cells grow very slowly, particularly after being thawed after
cryopreservation [31, 32]. However, while fewer ASCs are isolated per gram of adipose after long-term cryopreservation,

these cells maintain their robustness, perhaps suggesting that
surviving ASCs may harbor a certain protective advantage.
In support of this hypothesis is the observation that ASCs
from different cryopreservation groups expanded throughout
a 28-day time course grow at similar rates (Figures 3(a)–
3(c)). Our data further demonstrate that ASCs isolated from
adipose tissue that has been cryopreserved for long periods
of time retain their proliferative ability while maintaining their stemness (Figures 7(a)–7(c)). Taken together, our
observations suggest that differences in viability and growth
observed at initial ASC isolation relative to duration of
adipose tissue cryopreservation are deficits limited to early
cell isolation that are neutralized upon continued ASC expansion.
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Figure 4: Live ASC isolation relative to patient age. (a) ASCs were isolated from 32 patients of different ages (range 26–62 years, average
43.2 ± 9.7). Live ASCs isolated ranged from 0 to 95.5 × 104 cells/g adipose, average 63.8 ± 30.6, with no clear correlation between ASC
isolation and patient age. (b) Live cell count was compared relative to patient age across 4 cohort groups: <40 years (𝑁 = 12) versus ≥40 years
(𝑁 = 20); <50 years (𝑁 = 23) versus ≥50 years (𝑁 = 9); and <40 years (𝑁 = 12) versus ≥50 years (𝑁 = 9). No significant differences in live
ASC isolation were observed between any of the age cohorts; 𝑃 > 0.05.
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Figure 5: Initial ASC viability relative to patient age. (a) There was a modest trend toward increasing ASC viability with advancing patient
age. (b) ASC viability was compared relative to patient age across 4 cohort groups: <40 years (𝑁 = 12) versus ≥40 years (𝑁 = 20); <50 years
(𝑁 = 23) versus ≥50 years (𝑁 = 9); and <40 years (𝑁 = 12) versus ≥50 years (𝑁 = 9). No significant differences in ASC viability were
observed between any of the age cohorts; 𝑃 > 0.05.

Consequently, our data support whole adipose tissue
cryopreservation as a valuable method for long-term ASC
preservation. The observation that patient age had little
impact on initial cell number, viability, or long-term cell
growth further supports the suitability of this biobanking
technique (Figures 4–6) and the preservation of substantial
ASC counts even in fragile tissues from elderly patients that
may not tolerate additional interventions without significant
cellular loss. Importantly, the method of whole adipose
tissue cryopreservation avoids any potential adverse effects
caused by lipoaspirate-induced cellular trauma or the use
of cryopreservative media, further enhancing the utility of
this biobanking approach for clinical regenerative medicine
applications.

This study provides evidence that whole adipose tissue cryopreservation can serve as the gold standard for
long-term ASC biobanking. Because of the incremental
decrease in subcutaneous adipose tissue mass with advancing
patient age, it behooves us, when feasible, to bank this
valuable tissue prior to its diminution, ideally by middle
age. Additional studies are required to further elucidate
putative effects of long-term cryopreservation on precise
ASC functions and differentiation potentials in patients of
different ages. This is particularly important in light of recent
literature questioning the ability of directly cryopreserved
ASCs to undergo osteogenic differentiation [33, 34]. Future
investigations in cryopreserved whole adipose tissue will
be critical for the development of human adipose tissue
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Figure 6: Live ASCs during extended cell growth relative to patient age. ASCs from each patient were plated to a density of 1 × 105 cells/well
and viability was assayed after (a) 9, (b) 18, and (c) 28 days to characterize the effect of patient age on continued ASC viability. We observed
sustained ASC viability irrespective of patient age. Cell counts were compared relative to patients across 4 cohort groups: <40 years (𝑁 = 12)
versus ≥40 years (𝑁 = 20); <50 years (𝑁 = 23) versus ≥50 years (𝑁 = 9); and <40 years (𝑁 = 12) versus ≥50 years (𝑁 = 9). Live cell number
was not found to be significantly different in any of the comparisons.

banks and ASC isolation for regenerative medicine applications.

5. Conclusions
Adipose-derived stem cells are multipotent, abundant, and
easily isolated cells that represent a powerful tool for regenerative medicine. Unfortunately, much of the research regarding these cells is performed on fresh lipoaspirates that may
not be readily available in therapeutic clinical scenarios.
Though cryopreservation technologies continue to advance,
the effects of long-term adipose tissue cryopreservation on

ASC isolation have not been adequately characterized and
remain a limiting factor in advancing ASC-based regenerative medicine applications. Herein we demonstrate that longterm adipose tissue cryopreservation (>2 years at −70∘ C) does
significantly reduce the number of ASCs initially isolated per
gram of tissue. However, this primary attenuation in ASC
isolation is neutralized upon extended culturing as demonstrated by comparable ASC proliferative capacity, irrespective
of cryopreservation duration or patient age. Together, our
data suggest that ASCs are capable of enduring long-term
cryopreservation while maintaining their stemness, further
reinforcing their important contribution to regenerative
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Figure 7: ASC phenotype confirmation. (a) ASCs were analyzed via FACS analysis for the following markers: CD105, CD34, and CD45.
The data from representative patient cohorts are shown here. As predicted, the great majority of ASCs were CD105+ and CD45−, while the
CD34 marker showed variable expression (data not shown), consistent with prior studies. (b) ASCs isolated from all subgroups were capable
of undergoing both osteogenic and adipogenic differentiation, as demonstrated by positive staining with alkaline phosphatase and Oil Red
O, respectively. (c) Pluripotency gene expression was measured via qRT-PCR for Nanog, Sox2, and Oct4 and, as expected, was found to be
higher in ASCs compared to terminally differentiated IMR90 cells. ∗ 𝑃 < 0.05 and ∗∗ 𝑃 < 0.01.
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medicine applications. We anticipate that data such as those
reported here will be critical for the development of safe
and effective long-term human adipose tissue biobanking
technologies, optimization of ASC isolation protocols using
minimal tissue/cell processing, and validation of specific
clinical therapeutic applications for ASCs. In conclusion,
we advocate for whole adipose tissue cryopreservation in
preparation for future ASC-based regenerative medicine
therapies.

Conflict of Interests
The authors declare no conflict of interests regarding the
study described in this paper.

Acknowledgment
Funding for this work was provided by the University of
Pennsylvania Center for Human Appearance, the Department of Surgery and the Plastic Surgery Foundation.

References
[1] P. A. Zuk, M. Zhu, P. Ashjian et al., “Human adipose tissue is a
source of multipotent stem cells,” Molecular Biology of the Cell,
vol. 13, no. 12, pp. 4279–4295, 2002.
[2] P. A. Zuk, M. Zhu, H. Mizuno et al., “Multilineage cells from
human adipose tissue: implications for cell-based therapies,”
Tissue Engineering, vol. 7, no. 2, pp. 211–228, 2001.
[3] J. Shand, J. Berg, C. Bogue et al., “Human embryonic stem cell
(hESC) and human embryo research,” Pediatrics, vol. 130, no. 5,
pp. 972–977, 2012.
[4] J. M. Gimble, A. J. Katz, and B. A. Bunnell, “Adipose-derived
stem cells for regenerative medicine,” Circulation Research, vol.
100, no. 9, pp. 1249–1260, 2007.
[5] M. Dhanasekaran, S. Indumathi, R. Poojitha, A. Kanmani,
J. S. Rajkumar, and D. Sudarsanam, “Plasticity and banking
potential of cultured adipose tissue derived mesenchymal stem
cells,” Cell and Tissue Banking, vol. 14, no. 2, pp. 303–315, 2013.
[6] L. Casteilla, V. Planat-Bénard, B. Cousin et al., “Plasticity of
adipose tissue: a promising therapeutic avenue in the treatment
of cardiovascular and blood diseases?” Archives des Maladies du
Coeur et des Vaisseaux, vol. 98, no. 9, pp. 922–926, 2005.
[7] M. J. Oedayrajsingh-Varma, S. M. van Ham, M. Knippenberg
et al., “Adipose tissue-derived mesenchymal stem cell yield
and growth characteristics are affected by the tissue-harvesting
procedure,” Cytotherapy, vol. 8, no. 2, pp. 166–177, 2006.
[8] M. P. Francis, P. C. Sachs, L. W. Elmore, and S. E. Holt, “Isolating
adipose-derived mesenchymal stem cells from lipoaspirate
blood and saline fraction,” Organogenesis, vol. 6, no. 1, pp. 11–
14, 2010.
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